(Q36082073)

12 August 2017

1 reference

title

Enfuvirtide: the first HIV fusion inhibitor (English)

1 reference

12 August 2017

Adriano Lazzarin

1

0 references

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

1 reference

12 August 2017

6

1 reference

12 August 2017

453-464

1 reference

12 August 2017

3

1 reference

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

HIV fusion and its inhibition in antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

HIV entry and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Structural basis for membrane fusion by enveloped viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

A semiautomated fluorescence-based cell-to-cell fusion assay for gp120-gp41 and CD4 expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Are fusion inhibitors active against all HIV variants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Resistance to enfuvirtide, the first HIV fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Pharmacokinetics of enfuvirtide in a patient with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.453

21 January 2018

Identifiers

DOI

10.1517/14656566.6.3.453

1 reference

12 August 2017

1 reference

PubMed ID

15794736